Meeker David P Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
3
Insider Buys Sum
$851,713.00
Insider Sells Quantity
5
Insider Sells Sum
$2.81M

Insider Activity of Meeker David P

According to the SEC Form 4 filings, Meeker David P, being in a position of

  1. President and CEO at Rhythm Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 50000 shares for $5.13M,
    over all time since 2017-10-10, has bought 35000 shares for $626,713, and sold 157649 shares for $10.77M.

Biography of Meeker David P

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $5,133,4421100

Comparison of Insiders on Amount of Buys and Sells

2026-09-14SaleRhythm Pharmaceuticals, Inc.
RYTM
President and CEO
50,000
0.0731%
$102.67$5.13M-9.88%
2025-06-03SaleRhythm Pharmaceuticals, Inc.
RYTM
President and CEO
43,620
0.0679%
$65.05$2.84M+48%
2025-02-19SaleRhythm Pharmaceuticals, Inc.
RYTM
President and CEO
9,896
0.016%
$57.22$566,249+65.9%
2025-02-04SaleRhythm Pharmaceuticals, Inc.
RYTM
President and CEO
4,278
0.007%
$59.43$254,242+52.53%
2024-08-27SaleTrevi Therapeutics, Inc.
TRVI
director
4,555
0.0063%
$2.93$13,353+55.15%
2024-03-19SaleRhythm Pharmaceuticals, Inc.
RYTM
President and CEO
45,494
0.0758%
$39.22$1.78M+26.61%
2024-02-01SaleRhythm Pharmaceuticals, Inc.
RYTM
President and CEO
4,361
0.0073%
$45.06$196,507+2.85%
2021-03-30PurchaseRhythm Pharmaceuticals, Inc.
RYTM
President and CEO
10,000
0.0208%
$20.17$201,713-37.48%
2019-05-09PurchaseTrevi Therapeutics, Inc.
TRVI
22,500
0.1558%
$10.00$225,000-42.9%
2017-10-10PurchaseRhythm Pharmaceuticals, Inc.
RYTM
director
25,000
0.0624%
$17.00$425,000+9.57%
Total: 10
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.